ALK and non-small cell lung carcinoma: However, a comprehensive review of the literature published through December 2023 did not reveal any study that provided definitive recommendations for the optimal timing of radiotherapy and TKI in the treatment of BrM or LM from EGFRm or ALK + NSCLC.